NCT02833155View on ClinicalTrials.gov

Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

July 18, 2018

Study Completion Date

July 18, 2018

Conditions

Breast Cancer

Interventions

DRUG

Entinostat

Given PO

DRUG

Exemestane

Given PO

Trial Locations (4)

100021

Cancer Hospital Chinese Academy Medical Sciences, Beijing

300000

Tianjin Medical University Cancer Institute & Hospital, Tianjin

410013

Hunan Cancer Hospital, Changsha

610041

West China Hospital, Chengdu

All Listed Sponsors

lead

Taizhou EOC Pharma Co., Ltd.

INDUSTRY

NCT02833155 - Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter